Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) COO Sells 2,174 Shares of Stock

Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn sold 2,174 shares of the firm’s stock in a transaction that occurred on Tuesday, April 23rd. The shares were sold at an average price of $30.12, for a total transaction of $65,480.88. Following the completion of the sale, the chief operating officer now owns 176,206 shares of the company’s stock, valued at $5,307,324.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Patrick John Finn also recently made the following trade(s):

• On Tuesday, April 2nd, Patrick John Finn sold 492 shares of Twist Bioscience stock. The shares were sold at an average price of $32.74, for a total value of $16,108.08.

Twist Bioscience Stock Performance

Shares of TWST stock opened at $31.54 on Friday. The business has a fifty day moving average of $34.57 and a 200 day moving average of $30.42. Twist Bioscience Co. has a 1 year low of $11.46 and a 1 year high of $43.21.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Friday, February 2nd. The company reported ($0.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.03. The firm had revenue of $71.50 million during the quarter, compared to analysts’ expectations of $67.59 million. Twist Bioscience had a negative return on equity of 32.16% and a negative net margin of 78.44%. The company’s revenue for the quarter was up 31.8% compared to the same quarter last year. During the same period last year, the business posted ($0.74) earnings per share. Equities research analysts anticipate that Twist Bioscience Co. will post -3.17 EPS for the current year.

Institutional Trading of Twist Bioscience

Several institutional investors and hedge funds have recently bought and sold shares of the business. Federated Hermes Inc. purchased a new position in shares of Twist Bioscience during the third quarter worth $29,000. China Universal Asset Management Co. Ltd. grew its position in Twist Bioscience by 96.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,470 shares of the company’s stock worth $30,000 after purchasing an additional 721 shares during the period. EdgeRock Capital LLC purchased a new position in shares of Twist Bioscience during the 4th quarter valued at about $30,000. Allspring Global Investments Holdings LLC lifted its holdings in shares of Twist Bioscience by 51.8% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 3,453 shares of the company’s stock valued at $70,000 after buying an additional 1,179 shares during the period. Finally, International Assets Investment Management LLC lifted its holdings in shares of Twist Bioscience by 3,519.8% in the 4th quarter. International Assets Investment Management LLC now owns 4,018 shares of the company’s stock valued at $148,000 after buying an additional 3,907 shares during the period.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the company. Scotiabank upped their target price on Twist Bioscience from $30.00 to $43.00 and gave the company a “sector outperform” rating in a research report on Monday, February 5th. The Goldman Sachs Group upgraded Twist Bioscience from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $25.00 to $45.00 in a research note on Wednesday, January 17th. Finally, Barclays decreased their price objective on shares of Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating for the company in a research report on Wednesday, April 10th.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.